Literature DB >> 11936274

New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions.

Silvia Moretti1, Adelina Spallanzani, Lauretta Amato, Giuseppe Hautmann, Isabella Gallerani, Massimo Fabiani, Paolo Fabbri.   

Abstract

Vitiligo is a skin disease that is caused by selective destruction of melanocytes and is characterized by white spots. Melanocytes and keratinocytes seem to exhibit a functional close relationship, mediated at least in part by keratinocyte-derived cytokines, which seem important for survival and activity of melanocytic cells. We wanted to investigate the hypothesis that in vitiligo the expression of epidermal cytokines may be modified compared with normal skin. In 15 patients with active, non-segmental vitiligo, biopsies were obtained from lesional, perilesional and non-lesional skin; normal skin from five healthy donors was also tested. Tissue sections were tested using immunohistochemistry for the expression of keratinocyte-derived cytokines with stimulating activity, such as granulocyte-monocyte colony stimulating factor (GM-CSF), basic fibroblastic growth factor (bFGF), and stem cell factor (SCF) or with inhibiting activity, such as interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-alpha) on melanocytes. Cytokine receptors and specific melanocytic markers were also investigated. No melanocyte was identified in lesional skin by means of specific markers or c-kit receptor, whereas in perilesional, non-lesional and healthy skin, melanocytes were found in similar number. In vitiligo skin a significantly lower expression of GM-CSF, bFGF and SCF was found, and a significantly higher expression of IL-6 and TNF-alpha was detected, compared with perilesional, non-lesional and healthy skin. In conclusion, we provided evidence that a significant change of epidermal cytokines exists in vitiligo skin compared with perilesional, non-lesional and healthy skin, suggesting that the cytokine production of epidermal microenvironment may be involved in vitiligo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11936274     DOI: 10.1034/j.1600-0749.2002.1o049.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  52 in total

Review 1.  Hypopigmentary skin disorders: current treatment options and future directions.

Authors:  Anke Hartmann; Eva-B Bröcker; Jürgen C Becker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Functionally stable plasminogen activator inhibitor-1 in a family with cardiovascular disease and vitiligo.

Authors:  Mehmet Agirbasli; Mesut Eren; Songul Yasar; Kenan Delil; Fatih Goktay; Ebru Toksoy Oner; Douglas E Vaughan
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

3.  Epidermal permeability barrier recovery is delayed in vitiligo-involved sites.

Authors:  J Liu; W Y Man; C Z Lv; S P Song; Y J Shi; P M Elias; M Q Man
Journal:  Skin Pharmacol Physiol       Date:  2010-02-25       Impact factor: 3.479

4.  Effect of the Fructus Ligustri Lucidi extract and its monomers quercetin and oleanolic acid on the adhesion and migration of melanocytes and intracellular actin.

Authors:  Yanhua Wu; Qilin Li; Xiangjun Li; Danhua He; M U Niu; Xiaojuan Lu; Hui Li
Journal:  Biomed Rep       Date:  2016-03-23

Review 5.  Highlights in pathogenesis of vitiligo.

Authors:  Ghada F Mohammed; Amal Ha Gomaa; Mohammed Saleh Al-Dhubaibi
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

6.  [Vitiligo: Clinical presentation and pathogenesis].

Authors:  M Schild; M Meurer
Journal:  Hautarzt       Date:  2016-02       Impact factor: 0.751

7.  No Association between Vitiligo and Obesity: A Case-Control Study.

Authors:  Federica Dragoni; Rossana Conti; Simone Cazzaniga; Roberta Colucci; Lisa Pisaneschi; Luigi Naldi; Silvia Moretti
Journal:  Med Princ Pract       Date:  2017-09-12       Impact factor: 1.927

8.  Impact of HLA-G in the outcome of vitiligo in Tunisian patients.

Authors:  Akrem Jalel; Aouadi Ridha; Duboisier Laurent; Moureaux Philippe; M H Hamdaoui
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

9.  Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo.

Authors:  Mitesh Dwivedi; Naresh C Laddha; Kriti Shah; Bela J Shah; Rasheedunnisa Begum
Journal:  J Interferon Cytokine Res       Date:  2013-06-18       Impact factor: 2.607

10.  Lymphocyte imbalance in vitiligo patients indicated by elevated CD4+/CD8+ T-cell ratio.

Authors:  Robert Pichler; Konstantin Sfetsos; Birgit Badics; Sabrina Gutenbrunner; Jörg Berg; Josef Auböck
Journal:  Wien Med Wochenschr       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.